FindTrial
Sign In

Comparing the immune response between kidney transplant recipients with standard immunosuppressive regimen vs mycophenolic acid sparing regimen after extended primary series of two doses of Chadox-1 and single dose of BNT-162b2.

Comparing the immune response between kidney transplant recipients with standard immunosuppressive regimen vs mycophenolic acid sparing regimen after extended primary series of two doses of Chadox-1 and single dose of BNT-162b2.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20220402001
Enrollment
120
Registered
2022-04-02
Start date
2021-10-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immunological response after the booster dose of vaccine is given. covid vaccine kidney transplant BNT162b2

Interventions

receiving Tacrolimus + MPA,receiving mTORi + reduced dose Tacrolimus
Prevention,Prevention
KTR with standard immunosuppressive regimen ,KTR with mycophenolic acid sparing regimen

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: post kidney transplant > 6 months post ChAdOx-1 2 dosesage 18-70 YO

Exclusion criteria

Exclusion criteria: recently renal graft rejection active CMV, BK viremia, infection active malignancy pregnancy and breast feeding past COVID infection

Design outcomes

Primary

MeasureTime frame
anti SARS-CoV2 S antibody 4 weeks Elecsys, by Cobas e 411 analyzer; Roche Diagnostics, Basel, Switzerland—

Secondary

MeasureTime frame
anti HLA antibody 4 weeks PRA beads—

Countries

Thailand

Contacts

Public ContactSupitchaya Phirom

King Chula Memorial Hospital

pongphirom@gmail.com0847022286

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026